WQ5 Stock Overview
Operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genflow Biosciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.02 |
| 52 Week High | UK£0.036 |
| 52 Week Low | UK£0.012 |
| Beta | 2.32 |
| 1 Month Change | 11.11% |
| 3 Month Change | -14.89% |
| 1 Year Change | 11.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| WQ5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | 2.1% | -0.1% |
| 1Y | 11.1% | -9.7% | 7.4% |
Return vs Industry: WQ5 exceeded the German Biotechs industry which returned -9.7% over the past year.
Return vs Market: WQ5 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| WQ5 volatility | |
|---|---|
| WQ5 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WQ5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: WQ5's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Eric Leire | genflowbio.com |
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.
Genflow Biosciences plc Fundamentals Summary
| WQ5 fundamental statistics | |
|---|---|
| Market cap | €7.38m |
| Earnings (TTM) | -€1.85m |
| Revenue (TTM) | €721.20k |
10.2x
P/S Ratio-4.0x
P/E RatioIs WQ5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WQ5 income statement (TTM) | |
|---|---|
| Revenue | UK£598.04k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£598.04k |
| Other Expenses | UK£2.13m |
| Earnings | -UK£1.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -256.07% |
| Debt/Equity Ratio | 0% |
How did WQ5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 15:08 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genflow Biosciences plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|